Lilly, Rondo to collaborate on CD28 bispecific antibody development
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) has entered into a collaboration with Rondo Therapeutics for the development of CD28 bispecific antibodies for the treatment of solid tumors.
- Under the deal, Rondo will receive an upfront cash payment, plus potential milestone payments and tiered royalties on